Kidney Week

Abstract: SA-PO266

The Cure Glomerulonephropathy (CureGN) IgA Nephropathy and IgA Vasculitis Cohort

Session Information

• Clinical Glomerular Disorders: Vasculitis, C3G, IgAN
  November 04, 2017 | Location: Hall H, Morial Convention Center
  Abstract Time: 10:00 AM - 10:00 AM

Category: Glomerular

• 1005 Clinical Glomerular Disorders

Authors

• Selewski, David T., University of Michigan, Ann Arbor, Michigan, United States

David T. Selewski,

• Ambruzs, Josephine M., Arkana Laboratories, Little Rock, Arkansas, United States

Josephine M. Ambruzs,

• Appel, Gerald B., Columbia University College of Physicians and Surgeons, Scarsdale, New York, United States

Gerald B. Appel,

• Bomback, Andrew S., Columbia University, New York, New York, United States

Andrew S. Bomback,

• Cattran, Daniel C., Toronto General Hospital, Toronto, Ontario, Canada

Daniel C. Cattran,

• Fava, Melissa, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Melissa Fava,

• Gillespie, Brenda W., University of Michigan, Ann Arbor, Michigan, United States

Brenda W. Gillespie,

• Helmuth, Margaret, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Margaret Helmuth,

• Hogan, Jonathan J., Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania, United States

Jonathan J. Hogan,

• Julian, Bruce A., University of Alabama at Birmingham, Birmingham, Alabama, United States

Bruce A. Julian,

• Lafayette, Richard A., Stanford University, Stanford, California, United States

Richard A. Lafayette,

• Nachman, Patrick H., University of North Carolina School of Medicine , Chapel Hill, North Carolina, United States

Patrick H. Nachman,

• Nast, Cynthia C., Cedars-Sinai Medical Center, Los Angeles, California, United States

Cynthia C. Nast,

• Novak, Jan, University of Alabama at Birmingham, Birmingham, Alabama, United States

Jan Novak,

• O'Shaughnessy, Michelle M., Stanford University Medical Center, Palo Alto, California, United States

Michelle M. O'Shaughnessy,

• Palmer, Matthew, University of Pennsylvania , Philadelphia, Pennsylvania, United States

Matthew Palmer,

• Reich, Heather N., Toronto General Hospital, Toronto, Ontario, Canada

Heather N. Reich,

• Rizk, Dana, University of Alabama, Birmingham, Alabama, United States

Dana Rizk,

• Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Bruce M. Robinson,

• Sanghani, Neil S., Vanderbilt Nephrology, Nashville, Tennessee, United States

Neil S. Sanghani,

• Sexton, Melissa, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Melissa Sexton,

• Sperati, John, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

John Sperati,

• Zee, Jarcy, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Jarcy Zee,

• Kiryluk, Krzysztof, Columbia University, New York, New York, United States

Krzysztof Kiryluk,

Group or Team Name

• On behalf of the CureGN IgA writing group

Background

Cure Glomerulonephropathy (CureGN) is a multi-center(66 sites), NIDDK-funded longitudinal observational cohort study of 2400 prevalent (biopsy within 5 years) patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy (IgAN), including IgA vasculitis (IgAV, previously referred to as Henoch-Schonlein Purpura). We present enrollment data for the fully enrolled IgAN/IgAV cohort comparing children and adults.

Methods

Study data of 590 patients with biopsy confirmed IgAN or IgAV were reviewed. Lab and treatment data up to the time of enrollment are shown using descriptive statistics and univariate tests. We analyzed data to compare adults and children with IgAN and IgAV. Data are presented as median(IQR) and N(%).

Results

A total of 590 patients (355 adult and 235 pediatric) are in the IgAN/IgAV cohort. A comparison of adult to pediatric patients with IgAN and IgAV is in Table 1. Adults had lower eGFR at both time-points and lower enrollment albumin. For IgAN, adults had more proteinuria at both time-points. Patients with IgAV received more immunosuppression (83%v53%, p<0.001) and corticosteroids (81%v50%, p<0.001). 30% of children and 28% of adults with IgAV received either cyclophosphamide or mycophenolate mofetil.

Conclusion

This study reveals significant differences in the disease presentation and early disease course between children and adults with IgAV and IgAN. Furthermore, there were significant differences in treatments between IgAV and IgAN. This is the largest North American prospective IgAN/IgAV cohort initiated to date and will serve as an important resource to answer pathobiology questions in the future.

Table 1: Comparison of IgA Nephropathy and igA Vasculitis between Children and Adults

Funding

• NIDDK Support